Targeted natural product diversification to identify novel antibacterial agents

有针对性的天然产品多样化以确定新型抗菌剂

• 批准号: 8146429
• 负责人: Erin Elizabeth Carlson
• 金额: $ 105.6万
• 依托单位: TRUSTEES OF INDIANA UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-30 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8146429
• 关键词: Age; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics; Bacteria; Bacterial Drug Resistance; Biological Factors; Cause of Death; Combined Antibiotics; Communicable Diseases; Country; Development; Drug resistance; Goals; Infection; Microbe; Nature; Organism; Pharmaceutical Preparations; Plants; Public Health; Resistance; Technology; Therapeutic Agents; abstracting; antimicrobial; combat; drug discovery; improved; microorganism; mortality; next generation; novel; programs; public health relevance

DESCRIPTION (Provided by the applicant) Abstract: With the advent of the ""age of antibiotics"" in the 1940s, many believed that we had conquered these dangerous microbes. However, it quickly became apparent that the ability of bacteria to evolve resistance had been sorely underestimated and today, infectious diseases are the second-leading cause of death worldwide and the third-leading cause of mortality in economically advanced countries. The ever-growing and significant problem of antibacterial resistance requires discovery of new leads. However, identification of the next generations of antibiotics will necessitate a change in the curent drug discovery paradigm. Pursuit of compounds that function through the commonly targeted mechanisms of action will not yield the combination of antibiotic potency and long-term efficacy necessary to combat resistant organisms. In fact, compounds that attack microbes through multiple, simultaneous mechanisms will be essential to anti-infective development. Public Health Relevance: This program will improve public health through the identification of the next generation of antimicrobial therapeutic agents, particularly focusing on more effective and long-lifetime treatments for drug resistant infections. To achieve this goal, we will develop and apply technologies for the discovery of drug leads from nature's vast reservoir of antibacterial natural products from plants and microorganisms.

描述(由申请人提供) 摘要：随着20世纪40年代抗生素时代的到来，许多人认为我们已经征服了这些危险的微生物。然而，情况很快变得明显，细菌进化抗药性的能力被严重低估，今天，传染病是全球第二大死亡原因，也是经济发达国家的第三大死亡原因。日益严重的抗菌素耐药性问题需要发现新的线索。然而，识别下一代抗生素将需要改变目前的药物发现范式。追求通过共同靶向作用机制发挥作用的化合物将不会产生对抗耐药生物体所需的抗生素效力和长期疗效的组合。事实上，通过多个同步机制攻击微生物的化合物将是抗感染开发的关键。 公共卫生相关性：该计划将通过识别下一代抗菌治疗药物来改善公共健康，特别是关注更有效和更长期的耐药感染治疗。为了实现这一目标，我们将开发和应用从大自然巨大的植物和微生物抗菌天然产物中发现药物线索的技术。